Alterity Therapeutics Ltd
corporate_fare Company Profile
Alterity Therapeutics Ltd (NASDAQ:ATHE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for ATHE at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Formalizes 1-for-50 Reverse Stock Split, Details Timetable for Share Consolidation
- Shareholders to Vote on 1-for-50 Reverse Stock Split and Significant Director Option Grants
- Positive FDA Feedback Advances Alterity's ATH434 Phase 3 Program for MSA
- Alterity Therapeutics Secures Positive FDA Feedback on Manufacturing for ATH434 Phase 3 Program
- Substantial Holder's Percentage Ownership Drops, Signaling Significant Dilution
Financial Snapshot
Insider Transactions
ATHE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.